The US FDA has accepted for filing a resubmission of the New Drug Application for cladribine tablets by Merck; this could be a potential treatment for patients with relapsing forms of multiple sclerosis.
Browsing: Demyelinating disease
At the FENS Forum of Neuroscience (7–11 July, Berlin, Germany), researchers have come together to present their work on novel treatments for multiple sclerosis.
NICE has provisionally decided not to recommend ocrelizumab for patients with primary progressive multiple sclerosis on the NHS in England and Wales.
The second and final installment of our discussion focuses on the use of stem cells and what further research is on the horizons for multiple sclerosis.
In the first installment of this discussion, our experts discuss the mechanisms, therapies and challenges involved in multiple sclerosis research.
To mark World Multiple Sclerosis Day, we’re taking the opportunity to look back on some of the highlights in the field so far this year.
In this NCTalks podcast, we speak to Jens Kuhle to find out more about his work on monitoring multiple sclerosis using blood neurofilament light protein.
The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.
This week, our industry report covers neuroblastoma, DUB inhibitors for neurodegenerative diseases and pediatric multiple sclerosis.